Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06332781 · ClinicalTrials.gov registry record · Phase 4
Intravesical Gentamicin to Prevent Recurrent UTI
A Phase 4 study of Recurrent Uti, sponsored by Women and Infants Hospital of Rhode Island.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06332781: Recruiting Phase 4 study of Recurrent Uti, sponsored by Women and Infants Hospital of Rhode Island.
NCT06332781 is a Phase 4 study of Recurrent Uti that is actively recruiting participants, run by Women and Infants Hospital of Rhode Island. The registered enrollment target is 30 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06332781, a Phase 4 study of Recurrent Uti, is actively recruiting participants, sponsored by Women and Infants Hospital of Rhode Island.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Feasibility assessment of intravesical gentamicin instillation (putting antibiotics directly into the bladder) versus the current standard of care of oral nitrofurantoin prophylaxis (taking a low dose of antibiotics by mouth every day) to prevent recurrent urinary tract infections (UTI)
Primary Outcome
measure screening ratio (number of people screened versus number enrolled)
Conditions Studied
Interventions
- DRUG Nitrofurantoin
- DRUG Gentamicin
Study Locations (1)
Rhode Island
- Women & Infants Hospital - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-04-28 |
| Est. Completion | 2026-05-31 |
| Phase | Phase 4 |
What NCT06332781 shows while recruiting
NCT06332781 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Recurrent Uti appearing as the primary indexed condition, and to 2 interventions - of which Nitrofurantoin is the first listed.
NCT06332781 reports a single indexed study location in Rhode Island.
Frequently Asked Questions
What is clinical trial NCT06332781 about?
NCT06332781 is a clinical study titled "Intravesical Gentamicin to Prevent Recurrent UTI". Feasibility assessment of intravesical gentamicin instillation (putting antibiotics directly into the bladder) versus the current standard of care of oral nitrofurantoin prophylaxis (taking a low dose of antibiotics by mouth every day) to prevent recurrent urinary tract infections (UTI)
What is the current status of trial NCT06332781?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2025-04-28. Estimated completion is 2026-05-31.
What conditions does trial NCT06332781 study?
This clinical trial studies the following conditions: Recurrent Uti.
What interventions are being tested in trial NCT06332781?
The interventions under investigation include: Nitrofurantoin (DRUG), Gentamicin (DRUG).
Who is sponsoring clinical trial NCT06332781?
This trial is sponsored by Women and Infants Hospital of Rhode Island, which has 65 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06332781 being conducted?
This trial has 1 study location across Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Uti
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06332781's enrollment target sits among peer trials
30 1552nd of 2000 higher than 368 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI